YZYijun Zhou

Yijun Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yijun Zhou has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Renhua Lu

    Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Zhaohui Ni

    Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Bin Zhang

    Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    2 shared publications
  • Haifen Zhang

    Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    2 shared publications
  • Hao Yan

    Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    2 shared publications
  • Jianxiao Shen

    Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    2 shared publications

Latest Publications

  • Effects and Safety of Henagliflozin on Cardiac Structure in Patients with Heart Failure with Preserved Ejection Fraction on Dialysis

    by Hao Yan, Wei Wang, Wangshu Wu, Ying Li, Yinghui Qi, Yijun Zhou, Weiming Zhang, Shang Liu, Huihua Pang, Yan Fang, et al.

    Key Points: This trial evaluated the effects of henagliflozin on cardiac structure and its safety in patients with heart failure with preserved ejection fraction on dialysis. At week 24, henagliflozin achieved a statistically significant reduction in left ventricular mass index versus placebo (−5.27 g/m 2 ; 95% confidence interval, −10.02 to −0.53 g/m 2 ). Henagliflozin was tolerable in the peritoneal dialysis and hemodialysis settings. Background: Few effective drug treatments exist for patients with heart failure with preserved ejection fraction (HFpEF) on dialysis. The aim of this study was to evaluate the effects of henagliflozin, a sodium–glucose cotransporter 2 inhibitor, on cardiac structure and its safety in such population. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, patients with HFpEF on dialysis were randomly assigned (1:1) to receive henagliflozin or placebo for 24 weeks. All enrolled participants received conventional therapy. The primary outcome was change in left ventricular mass index (LVMI) from baseline to week 24. The secondary outcomes were changes in the left atrial volume index, E/e’, e’, and N -terminal pro-brain natriuretic peptide and safety. Efficacy was assessed in the intention-to-treat population. Safety was assessed in the as-treated population. Analysis of covariance was used to assess treatment effects. Results: A total of 112 participants were randomly assigned to the henagliflozin group ( n =56) and placebo group ( n =56). Of these, 60 participants were on hemodialysis and 52 were on peritoneal dialysis. From baseline to week 24, henagliflozin resulted in a greater reduction in least-squares mean (±SEM) change in LVMI than placebo (−3.27±1.71 g/m 2 versus 2.01±1.69 g/m 2 ), with a between-group difference of −5.27 g/m 2 (95% confidence interval [CI], −10.02 to −0.53 g/m 2 ; P = 0.03). In the prespecified subgroup by dialysis modality, the between-group difference in LVMI change from baseline to week 24 was −6.86 g/m 2 (95% CI, −14.02 to 0.29 g/m 2 ) among participants on peritoneal dialysis and −3.91 g/m 2 (95% CI, −10.45 to 2.63 g/m 2 ) among participants on hemodialysis. No between-group differences in secondary outcomes were observed. The incidence of adverse events was similar between the henagliflozin and placebo groups (36% versus 34%). Conclusions: Henagliflozin was associated with a greater reduction in LVMI at week 24 compared with placebo and was tolerable in patients with HFpEF on dialysis. Larger studies are needed to confirm the LVMI-lowering effect of henagliflozin. Clinical Trial registry name and registration number: ChiCTR2300073169.


  • Open Access

    Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial

    by Hao Yan, Wei Wang, Ying Li, Yinghui Qi, Renhua Lu, Yijun Zhou, Weiming Zhang, Shang Liu, Huihua Pang, Yan Fang, et al.

    Introduction: Heart failure with preserved ejection fraction (HFpEF) is a prevalent comorbidity among patients with end-stage kidney disease. Although sodium-glucose cotransporter 2 inhibitors are validated in treating heart failure and ameliorating left ventricular hypertrophy among non-dialysis patients, the effects on dialysis patients are unknown. We previously investigated the pharmacokinetics of henagliflozin in patients undergoing haemodialysis (HD) or peritoneal dialysis (PD) and clarified its safety. Methods and analysis: This multicentre, randomised, double-blind, placebo-controlled trial is being conducted at three hospitals in Shanghai, China. A target of 108 HD or PD patients with HFpEF are randomly allocated to treatment group (henagliflozin 5 mg/day in addition to standard therapy) or control group (placebo with standard therapy) at a ratio of 1:1. All subjects will be followed up for 24 weeks. The primary outcome is change in echocardiography-measured left ventricular mass index. The secondary interests include changes in left atrial volume index, E/e’, e’ and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Intergroup comparisons of change in echocardiography-related outcomes from baseline to 24 weeks are based on a linear regression model adjusted for baseline values (analysis of covariance), and repeated measure analysis of variance with Bonferroni adjustment is employed for comparison of change in NT-proBNP. Subgroup analyses of the primary and secondary outcomes are conducted to determine whether the effect of henagliflozin varies according to dialysis modality. The χ 2 method is used to compare the occurrence of adverse events and severe adverse events. Ethics and dissemination: This trial has been approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (LY2023-127-B). All participants provide written informed consent before screening. The results of the trial will be disclosed completely in international peer-reviewed journals. Both positive and negative results will be reported. Trial registration number: ChiCTR2300073169.


  • Open Access

    The initial attempt at home hemodialysis in mainland China

    by Zhaohui Ni, Yijun Zhou, Renhua Lu, Jianxiao Shen, Leyi Gu, Shan Mou, Li Zhao, Haifen Zhang, Bin Zhang, Yan Fang, et al.

    Background: Observational studies have shown home hemodialysis (HHD) to be associated with better survival than facility hemodialysis (HD) and peritoneal dialysis (PD). Patients on HHD have reported higher quality of life and independence. HHD is considered to be an economical way to manage end-stage kidney disease (ESKD). The coronavirus disease 2019 pandemic has had a significant impact on patients with ESKD. Patients on HHD may have an advantage over in-center HD patients because of a lower risk of exposure to infection. Participants and methods: We enrolled HD patients from our dialysis center. We first established the HHD training center. The training center was approved by the Chinese government. Doctors, nurses and engineers train and assess patients separately. There are three forms of patient monitoring: home visits, internet remote monitoring, and outpatient services. Demographic and medical data included age, sex, blood pressure, and dialysis-related data. Laboratory tests were conducted in our central testing laboratory, including hemoglobin (Hgb), serum creatinine (Cr), urea nitrogen (BUN), uric acid (UA), albumin (Alb), calcium (Ca), phosphorus (P), parathyroid hormone (PTH), and brain natriuretic peptide (BNP) levels. Results: Six patients who underwent regular dialysis in the HD center of our hospital were selected for HHD training. We enrolled 6 patients, including 4 males and 2 females. The mean age of the patients was 47.5 (34.7-55.7) years, and the mean dialysis age was 33.5 (11.2-41.5) months. After an average of 16.0 (11.2-25.5) months of training, Alb, P and BNP levels were improved compared with the baseline values. After training, three patients returned home to begin independent HD. During the follow-up, there were no serious adverse events leading to hospitalization or death, but there were several adverse events. They were solved quickly by extra home visits of the technicians or online by remote monitoring. During the follow-up time, the laboratory indicators of all the patients, including Hgb, Alb, Ca, P, PTH, BNP, and β2-MG levels, remained stable before and after HHD treatment. Conclusion: HHD is feasible and safe for ESKD in China, but larger-scale and longer-term studies are needed for further confirmation.


  • Open Access

    The initial attempt at home hemodialysis in mainland China

    by Zhaohui Ni, Yijun Zhou, Renhua Lu, Jianxiao Shen, Leyi Gu, Shan Mou, Li Zhao, Haifen Zhang, Bin Zhang, Yan Fang, et al.

    Background Observational studies showed home hemodialysis (HHD) to be associated with better survival than facility hemodialysis (HD) and peritoneal dialysis (PD). Patients on HHD have reported higher quality of life and independence. HHD is considered to be an economical way to manage end-stage kidney disease (ESKD). The coronavirus disease 2019 pandemic has had a significant impact on patients with ESKD. Patients on HHD may have an advantage over in-center HHD patients because of a lower risk of exposure to infection. Participants and Methods: We enrolled hemodialysis patients from our dialysis center. We estabilished HHD training center at first. The training center was approved by Chinese government. Doctors, nurses and engineers train and assess patients separately. There are three forms of patient monitoring: home visit, internet remote monitoring, and out-patient service. Demographic and medical data included age, gender, blood pressure, dialysis related data. Laboratory tests were conducted in our central testing laboratory including hemoglobin (Hgb), serum creatinine (Cr), urea nitrogen (BUN), uric acid (UA), albumin (Alb), calcium (Ca), phosphorus (P), parathyroid hormone (PTH), brain natriuretic peptide (BNP). Results Six patients who underwent regular dialysis in the hemodialysis center of our hospital were selected for HHD training. We enrolled 6 patients, including 4 males and 2 females. The mean age of the patients was 47.5 (34.7–55.7) years, the mean dialysis age was 33.5 (11.2–41.5) months. After an average of 16.0 (11.2–25.5) months of training, Alb, P and BNP were improved compared with baseline values. After training, three patients returned home to begin independent hemodialysis. During the follow-up, there are no serious adverse events leading to hospitalization or death, but there are several adverse events. They have been solved quickly by extra home visits of the technicians or online by remote monitoring. During the time, laboratory indicators of all the patients including Hgb, Alb, Ca, P, PTH, BNP, β2-MG remained stable before and after HHD treatment. Conclusion HHD is feasible and safe for ESRD in China, but larger-scale and longer-term studies are needed to further confirm.

  • Open Access

    Efficacy and safety of polysaccharide iron complex capsules compared with iron sucrose in hemodialysis patients: study protocol for a randomized, open-label, positive control, multicenter trial (IHOPE)

    by Renhua Lu, Xu Zhang, Xudong Cai, Xiaoxia Wang, Hua Li, Li Wang, Yijun Zhou, Jianxiao Shen, Qian Liu, Haifen Zhang, et al.

    Background: Anemia is one of the main complications of chronic kidney disease especially kidney failure, which includes treatment with erythropoiesis-stimulating agents and iron supplementation, including intravenous and oral iron. However, intravenous iron may pose limitations, such as potential infusion reactions. Oral iron is mainly composed of divalent iron, which can excessively stimulate the gastrointestinal tract. Iron polysaccharide complex capsules are a novel oral iron trivalent supplement with higher iron content and lower gastrointestinal irritation. However, since high-quality evidence-based medicinal support is lacking, it is necessary to conduct clinical studies to further evaluate the effectiveness and safety of oral iron polysaccharide complex in chronic kidney disease patients. Methods: This randomized controlled trial uses an open-label, parallel group design, where the efficacy and safety of maintenance hemodialysis (MHD) participants is evaluated. The experimental group is assigned erythropoietins and iron polysaccharide complex (two capsules each time, bid), and the control group is assigned erythropoietin and sucrose iron (100mg, 2w) injection. Participants (aged 18–75 years) undergoing maintenance hemodialysis were considered for screening. Inclusion criteria included hemoglobin (Hb) ≥110g/L and < 130g/L, transferrin saturation (TSAT) > 20% and < 50%, and serum ferritin (SF) > 200μg/L and < 500μg/L. Exclusion criteria included acute or chronic bleeding, serum albumin < 35g/L, hypersensitive C-reactive protein (HsCRP) > 10 mg/L, and severe secondary hyperparathyroidism (iPTH ≥ 800 pg/mL). Full inclusion and exclusion criteria are described in the “Methods” section. The primary endpoint is TSAT of the participants at week 12. Secondary endpoints include Hb, SF, hematocrit (Hct), HsCRP, pharmacoeconomic evaluation, drug costs, quality of life, and indicators of oxidative stress. The treatment will last for 24 weeks with a follow-up visit at baseline (within 7 days prior to initial treatment) and weeks 4, 8, 12, 16, 20, and 24 after initial treatment. This clinical research includes 9 hemodialysis centers in mainland China and plans to enroll 186 participants. Discussion: It is expected that it will provide strong evidence to reveal the clinical efficacy and safety of oral iron in the treatment of chronic CKD-related anemia in MHD patients through this clinical trial. Trial registration: Chinese Clinical Trial Registry ChiCTR2000031166. Registered on March 23, 2020


  • Open Access

    Investigation of the Mechanism Underlying Calcium Dobesilate-Mediated Improvement of Endothelial Dysfunction and Inflammation Caused by High Glucose

    by Yijun Zhou, Chaojun Qi, Shu Li, Xinghua Shao, Zhaohui Ni

    Background/Aims. Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease. Calcium dobesilate (CaD) is widely used to treat diabetic retinopathy. Recent studies have demonstrated that CaD exerts protective effects against diabetic nephropathy. The aim of this study was to elucidate the molecular and cellular mechanisms underlying the protective effects of CaD. Methods. Human umbilical vein endothelial cells (HUVECs) were cultured with different D-glucose concentrations to determine the effects of high glucose on HUVEC gene expression. HUVECs were also incubated with CaD (25 μM, 50 μM, and 100 μM) for 3 days to determine the effects of CaD on HUVEC viability. db/db mice were treated with CaD. 2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1) blocked the nuclear factor-κB (NF-κB) pathway in HUVECs. A pentraxin 3 (PTX3) small interfering RNA (siRNA) intervention experiment was performed in the cells. An adenovirus-encapsulated PTX3 siRNA intervention experiment was performed in db/db mice. Western blot and real-time PCR analyses were used to detect PTX3, p-IKBa/IKBa (I-kappa-B-alpha), and p-eNOS/eNOS (endothelial nitric oxide synthase) expression in mice and HUVECs. Hematoxylin-eosin (HE) staining and periodic acid-Schiff (PAS) staining were used to observe renal tissue damage in mice. PTX3 expression was observed by immunohistochemical staining. Results. CaD downregulated the expression of PTX3 and p-IKBa/IKBa and upregulated the expression of p-eNOS/eNOS in vitro. When TPCA-1 was used, high glucose induced high PTX3 expression, and the expression of p-eNOS/eNOS increased. After PTX3 gene silencing, the expression of p-eNOS/eNOS also increased. In vivo, CaD reduced the expression of PTX3 and p-IKBa/IKBa in the kidneys of db/db mice and increased the expression of p-eNOS/eNOS. After PTX3 gene silencing, the urine protein and renal function of db/db mice were ameliorated, the glomerular extracellular matrix was decreased, and the expression of p-eNOS/eNOS was increased. Conclusions. Our results suggested that CaD may inhibit the expression of PTX3 by altering the IKK/IKB/NF-κB pathway, thereby improving endothelial dysfunction in HUVECs. PTX3 may be a potential therapeutic target for DKD.